In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
News|Videos|May 8, 2026
5 Hepatology Headlines You Missed in April 2026
Author(s)Abigail Brooks, MA
Fact checked by: Alex Hillenbrand
Catch up on updates in viral hepatitis treatment, advances in rare liver disease care, and more.
Advertisement
Advertisement
April brought a series of important developments in hepatology, with advances in chronic viral hepatitis, rare cholestatic liver diseases, and precision medicine continuing to shape the field. From regulatory momentum in
Related to this article
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Real-world data at AASLD 2026 show 37% to 55% of patients with MASH on resmetirom (Rezdiffra) improved liver stiffness by 25% or more at about one year.
October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement